Genus reports progress amid market challenges, eyes FDA approval By Investing.com
Genus PLC (GNS), a leading animal genetics company, reported its preliminary results for the fiscal year ended June 30, 2024, showcasing resilience and strategic advancements despite challenging trading conditions. CEO Jorgen Kokke…
